<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916132</url>
  </required_header>
  <id_info>
    <org_study_id>PRIMETIME2</org_study_id>
    <secondary_id>H-20080050</secondary_id>
    <nct_id>NCT04916132</nct_id>
  </id_info>
  <brief_title>Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors</brief_title>
  <acronym>PRIMETIME WP2</acronym>
  <official_title>Biopsy-proven Diabetic Nephropathy in People With Type 2 Diabetes. Prevalence and Predictive Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holbaek Sygehus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Slagelse Sygehus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nyk√∏bing Falster County Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gubra ApS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Novo Nordisk Foundation Center for Basic Metabolic Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kidney Precision medicine Project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      a prospective, observational, multi-center study with a cohort of 300 patients with Type 2&#xD;
      diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the&#xD;
      transciptome of the kidney tissue and other biomarkers from blood, faeces, urine, proteomic-&#xD;
      and metabolomic profiles and DNA-variants. Thereby we hope to be able to discover molecular&#xD;
      and clinical profiles, that can help us in the diagnosis of DKD, and to identify different&#xD;
      risks of progression that can benefit from different forms of personalized treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PRIMETIME project is made to bring together molecular, translational and clinical&#xD;
      scientists to create collaborations and build a scientific bridge between diabetology,&#xD;
      nephrology, clinical biochemistry, and pathology. The ultimately goal is to bring forward an&#xD;
      improved understanding of the most frequent cause of end stage renal disease: DKD. We aim to&#xD;
      improve the diagnostic accuracy as well as the treatment precision by investigating in detail&#xD;
      the features of histology and protein expression in both retrospective(WP1) and&#xD;
      prospective(WP2) kidney biopsy material.&#xD;
&#xD;
      PRIMETIME WP2 is a prospective, observational, multi-center study with a cohort of 300&#xD;
      patients. We plan to create a systematically unselected cohort of patients with Type2&#xD;
      diabetes and macroalbuminuria as a sign of kidney injury. Prospectively we will collect&#xD;
      research kidney biopsies and other biomarkers from blood, faeces, urine, proteomic- and&#xD;
      metabolomic profiles and DNA-variants. The biopsies will be thoroughly investigated with&#xD;
      cutting-edge molecular technologies and associated to the biomarkers, disease course and&#xD;
      clinical outcome. The participants will afterward be followed in 20 years.Thereby we hope to&#xD;
      be able to discover molecular and clinical profiles, that can help us in the diagnosis of&#xD;
      DKD, and to identify different risks of progression that can benefit from different forms of&#xD;
      personalized treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2043</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2043</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence</measure>
    <time_frame>From baseline to end inclusion (3 years)</time_frame>
    <description>To investigate the prevalence of biopsy-proven diabetic nephropathy in individuals with T2DM with severe albuminuria; urine albumin/creatinine ratio (UACR) &gt;700 mg/g.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved clinical diagnosis</measure>
    <time_frame>From baseline to end inclusion (3 years)</time_frame>
    <description>To investigate whether clinical variables, transcriptomic, proteomic and/or metabolomic profiles as well as genetic variation can predict the presence of diabetic nephropathy in a kidney biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diabetic retinopathy</measure>
    <time_frame>From baseline to end inclusion (3 years)</time_frame>
    <description>To describe the sensitivity and specificity of diabetic retinopathy in predicting biopsy-proven diabetic nephropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Biopsy</measure>
    <time_frame>From baseline to end of followup (20 years)</time_frame>
    <description>describe the prognostic value of different histological and molecular findings on kidney biopsy in individuals with biopsy-proven diabetic nephropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-diabetic nephropathy vs. biopsy-proven diabetic nephropathy</measure>
    <time_frame>From baseline to end of followup (20 years)</time_frame>
    <description>describe the prognostic value of different histological and molecular findings on the kidney biopsy in individuals with non-diabetic nephropathy compared to biopsy-proven diabetic nephropathy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proteomic and metabolomic</measure>
    <time_frame>From baseline to end of followup (20 years)</time_frame>
    <description>describe the prognostic value of the proteomic and metabolomic profiles in biopsy-proven diabetic nephropathy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>genetic variants</measure>
    <time_frame>From baseline to end of followup (20 years)</time_frame>
    <description>describe the prognostic value of different forms of genetic variation in biopsy-proven diabetic nephropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiome</measure>
    <time_frame>From baseline to end of followup (20 years)</time_frame>
    <description>describe the prognostic value of different compositions of the microbiome and its relation to biopsy and clinical findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual changes in kidney status</measure>
    <time_frame>From baseline to end of followup (20 years)</time_frame>
    <description>Annual changes in kidney status (defined by yes/no: initiation of dialysis, kidney transplantation, renal death or decrease in eGFR &gt; 40 % compared to eGFR at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual decline in eGRF</measure>
    <time_frame>From baseline to end of followup (20 years)</time_frame>
    <description>Annual decline in eGRF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual changes in albuminuria.</measure>
    <time_frame>From baseline to end of followup (20 years)</time_frame>
    <description>Annual changes in albuminuria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual events of cardiovascular disease</measure>
    <time_frame>From baseline to end of followup (20 years)</time_frame>
    <description>Events of cardiovascular disease (fatal CV events, non-fatal stroke, non-fatal myocardial infarction, hospitalization for heart failure, PCI or bypass surgery (heart or legs), amputations due to ischemia, and unstable angina)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>From baseline to end of followup (20 years)</time_frame>
    <description>Death (any cause).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Albuminuria</condition>
  <condition>Diabetic Kidney Disease</condition>
  <condition>Diabetic Nephropathies</condition>
  <condition>Diabetes type2</condition>
  <condition>Molecular Sequence Variation</condition>
  <condition>Kidney Biopsy</condition>
  <arm_group>
    <arm_group_label>Peolpe with T2DM and albuminuria</arm_group_label>
    <description>Prospectively we will collect research kidney biopsies and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. The biopsies will be thoroughly investigated with cutting-edge molecular technologies and associated to the biomarkers, disease course and clinical outcome.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Kidney Biopsy</intervention_name>
    <description>Harvesting of kidney tissue from people with type 2 diabetes and albuminuria for subsequent analysis</description>
    <arm_group_label>Peolpe with T2DM and albuminuria</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Kidney Biopsy (histological and RNA-sequencing) Blood (proteomics, metabolomics and&#xD;
      wholegenome sequencing) Urine (Proteomics and metabolomics) Faecal and salvia samples&#xD;
      (analysis om the microbiom)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People with type 2 diabetes, albuminuria and eGFR &gt; 30 who are willing to undergo a kidney&#xD;
        biopsy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ‚â• 18 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Diagnosis with T2DM according to the American diabetes Association (20)&#xD;
&#xD;
          -  eGFR &gt;30 mL/min/1.73 m2 (maximum six months old)&#xD;
&#xD;
          -  urine-albumin/creatinine-ratio (uACR) &gt; 700 mg/g or 24 hours urine albumin &gt;700 mg on&#xD;
             more than one measurement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Signs of acute kidney failure according to the KDIGO classification (21) at the time&#xD;
             for kidney biopsy or the last 6 months before kidney biopsy&#xD;
&#xD;
          -  Factors that increases the risk of complications due to kidney biopsy:&#xD;
&#xD;
               -  Hemoglobin &lt; 6 mmol/L&#xD;
&#xD;
               -  INR &gt;1,4 at the time for biopsy&#xD;
&#xD;
               -  Platelet count &lt; 100 x 109/l&#xD;
&#xD;
               -  Uncontrolled high blood pressure (defined as systolic blood pressure &gt; 160 mmHg&#xD;
                  and/or diastolic blood pressure &gt; 100 mmHg)&#xD;
&#xD;
               -  Only one functioning kidney&#xD;
&#xD;
               -  Evidence of urinary tract obstruction or hydronephrosis at the time of biopsy&#xD;
&#xD;
               -  Multiple bilateral kidney cysts&#xD;
&#xD;
               -  Kidney infection, peri-renal infection, or cutaneous infection that overlies the&#xD;
                  kidney at time for biopsy&#xD;
&#xD;
               -  Unwilling to receive blood transfusion&#xD;
&#xD;
               -  Unable to lie flat in bed six hours after biopsy&#xD;
&#xD;
               -  Any other contra-indications for percutaneous kidney biopsy according to local&#xD;
                  clinical guidelines&#xD;
&#xD;
          -  Unable to understand written and oral information&#xD;
&#xD;
          -  Kidney transplant recipient&#xD;
&#xD;
          -  Women who are pregnant or planning to become pregnant before the kidney biopsy is&#xD;
             performed&#xD;
&#xD;
          -  Treatment with Marcoumar (all other anticoagulants are accepted)&#xD;
&#xD;
          -  High thromboembolic risk combined with held in anticoagulation therapy according to&#xD;
             the report &quot;Perioperative regulation of antithrombotic treatment&quot; (PRAB) (22)&#xD;
&#xD;
               -  mechanical heart valve&#xD;
&#xD;
               -  atrial fibrillation AND CHA2DS2-VASc&gt; 5 and/or stroke within the last three&#xD;
                  months&#xD;
&#xD;
               -  recurrent venous thromboembolism OR venous thromboembolism within the last three&#xD;
                  months&#xD;
&#xD;
               -  less than 6 weeks after uncomplicated Acute Coronary Syndrome (ACS) with or&#xD;
                  without revascularization (Percutaneous Coronary Intervention (PCI)) with Bare&#xD;
                  Metal Stents (BMS) or Coronary Artery Bypass Grafting (CABG))&#xD;
&#xD;
               -  less than 3 months after uncomplicated ACS with revascularization (PCI with Drug&#xD;
                  Eluting Stent (DES))&#xD;
&#xD;
               -  less than 9-12 months after complicated ACS (e.g. reinfarction or stent&#xD;
                  thrombosis)&#xD;
&#xD;
               -  less than 1 month after revascularization in individuals with stable Coronary&#xD;
                  Artery Disease (CAD) (PCI with BMS or CABG)&#xD;
&#xD;
               -  less than 3 months after revascularization in individuals with stable CAD (PCI&#xD;
                  with DES)&#xD;
&#xD;
               -  less than 3 months after stroke, or Transient Ischemic Attack (TIA)&#xD;
&#xD;
          -  Inability to withdraw nonsteroidal anti-inflammatory drugs (NSAID) 7 days before&#xD;
             biopsy&#xD;
&#xD;
        If a participant meets one or more exclusion criteria, that are reversible, the participant&#xD;
        can be rescreened later on, to evaluate whether or not the participant now is qualified for&#xD;
        participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Frederik Persson, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie M√∏ller</last_name>
    <phone>+4561695364</phone>
    <email>marie.moeller@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ditte Hansen</last_name>
    <phone>+4538682056</phone>
    <email>ditte.hansen.04@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus Universitetshospital, Skejby</name>
      <address>
        <city>Skejby</city>
        <state>Aarhus</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Johan V Povlsen, MD, PhD</last_name>
      <email>johan.povlsen@skejby.rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>S√∏ren T Knudsen</last_name>
      <email>soerknud@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <state>Gentofte</state>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter C Rossing, MD, PHD, PROF</last_name>
      <email>peter.rossing@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Frederik Persson, MD, MDSc</last_name>
      <phone>+4527512622</phone>
      <email>frederik.persson@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>K√∏benhavn √ò</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Mads Copenhagen, MD, PhD</last_name>
      <email>mads.hornum@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Almdal, MD, MDSc</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nyk√∏bing Falster Sygehus</name>
      <address>
        <city>Nyk√∏bing Falster</city>
        <state>Nyk√∏bing F</state>
        <zip>4800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie M√∏ller, MD</last_name>
      <phone>+4561695364</phone>
      <email>marie.moeller@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ditte Hansen, MD, PhD</last_name>
      <phone>+4538682056</phone>
      <email>ditte.hansen.04@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Iain Bressendorff, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bo Broberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kristine D Schandorff</name>
      <address>
        <city>Hiller√∏d</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Kristine D Schandorff, MD</last_name>
      <email>kristine.dyhr.schandorff@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Signe SS Rasmussen, MD, PhD</last_name>
      <email>signe.sabine.saetre.rasmussen@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Holb√¶k Hospital</name>
      <address>
        <city>Holb√¶k</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Morten Lindhardt, MD, PhD</last_name>
      <email>moli@regionsjaelland.dk</email>
    </contact>
    <contact_backup>
      <last_name>Jesper O Christensen, MD, PhD</last_name>
      <email>joc@regionsjaelland.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sj√¶llands Universitetshospital, K√∏ge</name>
      <address>
        <city>K√∏ge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Urd L Kielgast, MD, PhD</last_name>
      <email>ulki@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sj√¶llands Universitetshospital, Roskilde</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Rikke Borg, MD, PhD</last_name>
      <phone>+4530223200</phone>
      <email>rbor@regionsjaelland.dk</email>
    </contact>
    <contact_backup>
      <last_name>Karina H Jensen, MD</last_name>
      <email>khr@regionsjaelland.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Bjarne √òrskov, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slagelse Sygehus</name>
      <address>
        <city>Slagelse</city>
        <zip>4200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Eva M Lerche-Black, MD, PhD</last_name>
      <email>emle@regionsjaelland.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Marie M√∏ller</investigator_full_name>
    <investigator_title>MD, PhD-student</investigator_title>
  </responsible_party>
  <keyword>diabetic nephropaty</keyword>
  <keyword>precision medicine</keyword>
  <keyword>kidney biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>This topic is still up for discussion. We do plan to share most of the data, but how, time and place are still undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

